NBTX Stock Analysis: Buy, Sell, or Hold?
NBTX - Nanobiotix S.A. American Depositary Shares
$34.15
-2.45 (-6.69%)
▼
5d:
-5.11%
30d:
-16.73%
90d:
+16.67%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Apr 28, 2026
0d
Get Alerted When NBTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NBTX trades at premium valuation expecting 44.8% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: NBTX trades at premium valuation expecting 44.8% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: NBTX is currently trading at $34.15, which is considered oversold relative to its 30-day fair value range of $34.33 to $41.86. From a valuation perspective, the stock is trading at a premium (Forward PE: 541.4) compared to its historical average (178.3). At these levels, the market is pricing in 44.8% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, NBTX is in a uptrend. Immediate support is located at $31.71, while resistance sits at $38.29. Short-term momentum is weak, with the stock down 6.7% recently.
Market Sentiment: NBTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $43.42 (+18.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NBTX is in a uptrend. Immediate support is located at $31.71, while resistance sits at $38.29. Short-term momentum is weak, with the stock down 6.7% recently.
Market Sentiment: NBTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $43.42 (+18.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$34.33 -
$41.86
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
45.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.7%)
- BULLISH: Trading below Wall St target ($43.42)
- BEARISH: Market expects 44.8% growth - appears too optimistic based on history
- CAUTION: 5-day price weakness (-5.1%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$34.33 -
$41.86
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$31.71
Resistance Level
$38.29
Current Trend
Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
541.42
Wall Street Target
$43.42
(+18.6%)
Revenue Growth (YoY)
186.8%
Profit Margin
-73.5%
Valuation Premium vs History
+44.8% premium
PE vs Historical
541.4 vs 178.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+44.8%
(market-implied from PE analysis)
1-Year Target
$53.00
(+45%)
2-Year Target
$76.74
(+110%)
3-Year Target
$111.12
(+204%)
3-Yr Target (if PE normalizes)
(PE: 541→178)
PE COMPRESSION
$36.59
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 541.4, Growth: 59.1%)
$123.52
(+238%)
Base:
(SPY PE: 21.8, Growth: 59.1%)
$4.97
(-86%)
Bear:
(PE: 18.5, Growth: 59.1%)
$4.22
(-89%)
Share & Embed Analysis
Last updated: June 24, 2026 1:14 PM ET
Data refreshes hourly during market hours. Next update: 2:14 PM
Data refreshes hourly during market hours. Next update: 2:14 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 57 HOLD |
